Machine learning-based diagnostics startup Dascena Inc. has won the U.S. FDA’s breakthrough device designation for its Previse algorithm, which is designed to predict acute kidney injury (AKI) before clinical symptoms. In early validation tests, Previse detected AKI more than a day before patients exhibited kidney damage or impaired function.

A long-term clinical trial comparing minimally invasive cryoablation to surgery to treat early stage kidney cancer patients has found that the former offers comparable rates of survival and fewer complications. Johns Hopkins researchers published the 10-year survival data for 134 patients in the June 9, 2020, issue of Radiology.